AR073631A1 - Antagonistas del receptor transitorio potencial de vanilloides 1 ( trpv1) utiles para tratar inflamacion y dolor - Google Patents

Antagonistas del receptor transitorio potencial de vanilloides 1 ( trpv1) utiles para tratar inflamacion y dolor

Info

Publication number
AR073631A1
AR073631A1 ARP090103975A ARP090103975A AR073631A1 AR 073631 A1 AR073631 A1 AR 073631A1 AR P090103975 A ARP090103975 A AR P090103975A AR P090103975 A ARP090103975 A AR P090103975A AR 073631 A1 AR073631 A1 AR 073631A1
Authority
AR
Argentina
Prior art keywords
dihydro
urea
indazol
chromen
benzopyran
Prior art date
Application number
ARP090103975A
Other languages
English (en)
Inventor
Robert G Schimidt
Arthur R Gomtsyan
Eric A Voight
Michael E Kort
Philip R Kym
Heath A Mcdonald
Erol K Bayburt
Jun Chen
Jerome F Daanen
Jr Stanley Didomenico
Richard J Perner
Original Assignee
Abbott Lab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Abbott Lab filed Critical Abbott Lab
Publication of AR073631A1 publication Critical patent/AR073631A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D311/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings
    • C07D311/02—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D311/74—Benzo[b]pyrans, hydrogenated in the carbocyclic ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/08—Bronchodilators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/14—Antitussive agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/10—Drugs for disorders of the urinary system of the bladder
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Urology & Nephrology (AREA)
  • Pulmonology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Rheumatology (AREA)
  • Diabetes (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Obesity (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Pain & Pain Management (AREA)
  • Child & Adolescent Psychology (AREA)
  • Vascular Medicine (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Hematology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Hospice & Palliative Care (AREA)
  • Otolaryngology (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Pyrane Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Reivindicacion 1: Un compuesto caracterizado porque responde a la formula (1) o una sal solvato, prodroga, sal de una prodroga aceptables para uso farmacéutico, o una combinacion de los mismos, donde R1 representa un grupo de formula (a), (b), (c) o (d); Rx, en cada caso, representa sustituyente(s) opcional(es) sobre cualquier posicion sustituible del anillo bicíclico seleccionados entre el grupo que consiste de alquilo, halogeno, haloalquilo, OH, O(alquilo), O(haloalquilo), NH2, N(H)(alquilo), y N(alquilo)2; Ra es hidrogeno o metilo; R2 y R3 son iguales o diferentes, y son cada uno en forma independiente hidrogeno, alquilo C1-5, o haloalquilo; o R2 y R3, junto con el átomo de carbono al cual se encuentran unidos, forman un anillo cicloalquilo monocíclico de 3 a 6 átomos de carbono, opcionalmente sustituido con 1, 2 o 3 sustituyentes seleccionados entre el grupo que consiste de alquilo y halogeno; R4 en cada caso, representa sustituyente(s) opcional(es) sobre cualquier posicion sustituible del anillo bicíclico seleccionados entre el grupo que consiste de alquilo, halogeno, haloalquilo, O(alquilo), O(haloalquilo), y SCF3; y m y n son cada uno en forma independiente 0, 1, 2 o 3; con la condicion de que el compuesto no es N-(7-tert-butil-3,4-dihidro-2H-cromen-4-il)-N'-1H-indazol-4-ilurea; N-1H-indazol-4-il-N'-[7-(trifluorometil)-3,4-dihidro-2H-cromen-4-il]urea; N-isoquinolin-5-il-N'-[7-(trifluorometil)-3,4-dihidro-2H-cromen-4-il]urea; N-1H-indazol-4-il-N'-(6-metil-3,4-dihidro-2H-cromen-4-il)urea; N-isoquinolin-5-il-N'-(6-metil-3,4-dihidro-2H-cromen-4-il)urea; N-(6-fluoro-3,4-dihidro-2H-cromen-4-il)-N'-1H-indazol-4-ilurea; N-(6-fluoro-3,4-dihidro-2H-cromen-4-il)-N'-isoquinolin-5-ilurea; N-(6-cloro-7-metil-3,4-dihidro-2H-cromen-4-il)-N'-1H-indazol-4-ilurea; N-(6-cloro-7-metil-3,4-dihidro-2H-cromen-4-il)-N'-isoquinolin-5-ilurea; N-3,4-dihidro-2H-cromen-4-il-N'-1H-indazol-4-ilurea; N-(7-tert-butil-3,4-dihidro-2H-cromen-4-il)-N'-(3metilisoquinolin-5-il)urea; N-(6-fluoro-3,4-dihidro-2H-cromen-4-il)-N'-(3-metilisoquinolin-5-il)urea; N-(6-metil-3,4-dihidro-2H-cromen-4-il)-N'-(3-metilisoquinolin-5-il)urea; N-isoquinolin-5-il-N'-(8-piperidin-1-il-3,4-dihidro-2H-cromen-4-il)urea; N-3,4-dihidro-2H-cromen-4-il-N'-isoquinolin-5-ilurea; (+)-N-isoquinolin-5-il-N'-[7-(trifluorometil)-3,4-dihidro-2H-cromen-4-il]urea; (-)-N-isoquinolin-5-il-N'-[7-(trifluorometil)-3,4-dihidro-2H-cromen-4-il]urea; N-1H-indazol-4-il-N'-[8-(trifluorometil)-3,4-dihidro-2H-cromen-4-il]urea; (-)-N-1H-indazol-4-il-N'-[7-(trifluorometil)-3,4-dihidro-2H-cromen-4-il]urea; (+)-N-1H-indazol-4-il-N'-[7-(trifluorometil)-3,4-dihidro-2H-cromen-4-il]urea; N-1H-indazol-4-il-N'-(8-piperidin-1-il-3,4-dihidro-2H-cromen-4-il)urea; N-(8-tert-butil-3,4-dihidro-2H-cromen-4-il)-N'-1H-indazol-4-ilurea; N-[8-cloro-7-(trifluorometil)-3,4-dihidro-2H-cromen-4-il]-N'-1H-indazol-4-ilurea; (+)-N-(8-tert-butil-3,4-dihidro-2H-cromen-4-il)-N'-1H-indazol-4-ilurea; (-)-N-(8-tert-butil-3,4-dihidro-2H-cromen-4-il)-N'-1H-indazol-4-ilurea; N-1H-indazol-4-il-N'-[8-(trifluorometoxi)-3,4-dihidro-2H-cromen-4-il]urea; N-[8-fluoro-7-(trifluorometil)-3,4-dihidro-2H-cromen-4-il]-N'-1H-indazol-4-ilurea; N-1H-indazol-4-il-N'-[7-(trifluorometoxi)-3,4-dihidro-2H-cromen-4-il]urea; N-(6-fluoro-2-metil-3,4-dihidro-2H-cromen-4-il)-N'-1H-indazol-4-ilurea; N-1H-indazol-4-il-N'-(7-metoxi-2,2-dimetil-3,4-dihidro-2H-cromen-4-il)urea; N-1H-indazol-4-il-N'-(7-metoxi-2,2,8-trimetil-3,4-dihidro-2H-cromen-4-il)urea; N-1H-indazol-4-il-N'-(2,2,8-trimetil-3,4-dihidro-2H-cromen-4-il)urea; N-1H-indazol-4-il-N'-(7-metoxi-2,2-dimetil-8-propil-3,4-dihidro-2H-cromen-4-il)urea; N-(2,2-dimetil-3,4-dihidro-2H-cromen-4-il)-N'-1H-indazol-4-ilurea; N-(7-fluoro-2,2-dimetil-3,4-dihidro-2H-cromen-4-il)-N'-1H-indazol-4-ilurea; N-(7-fluoro-2,2-dietil-3,4-dihidro-2H-cromen-4-il)-N'-1H-indazol-4-ilurea; N-(7,8-difluoro-2,2-dimetil-3,4-dihidro-2H-cromen-4-il)-N'-1H-indazol-4-ilurea; N-(7-(3,3-dimetilbutil)-3,4-dihidro-2H-cromen-4-il)-N'-1H-indazol-4-ilurea; N-(7-tert-butil-2,2-dimetil-3,4-dihidro-2H-cromen-4-il)-N'-1H-indazol-4-ilurea; N-(2,2-dietil-7-fluoro-3,4-dihidro-2H-cromen-4-il)-N'-(1-metil-1H-indazol-4-il)urea; N-(7,8-difluoro-3,4-dihidro-2H-cromen-4-il)-N'-1H-indazol-4-ilurea; N-(7-fluoro-2,2-dipropil-3,4-dihidro-2H-cromen-4-il)-N'-1H-indazol-4-ilurea; N-(2,2-dibutil-7-fluoro-3,4-dihidro-2H-cromen-4-il)-N'-1H-indazol-4-ilurea; N-(2-tert-butil-7-fluoro-3,4-dihidro-2H-cromen-4-il)-N'-1H-indazol-4-ilurea; N-(2-tert-butil-7-fluoro-3,4-dihidro-2H-cromen-4-il)-N'-(1-metil-1H-indazol-4-il)urea; N-(8-tert-butil-3,4-dihidro-2H-cromen-4-il)-N'-(7-hidroxi-5,6,7,8-tetrahidronaftalen-1-il)urea; N-(7-hidroxi-5,6,7,8-tetrahidronaftalen-1-il)-N'-(6-metil-3,4-dihidro-2H-cromen-4-il)urea; N-[(4R)-3,4-dihidro-2H-cromen-4-il]-N'-(7-hidroxi-5,6,7,8-tetrahidronaftalen-1-il)urea; N-[(4S)-3,4-dihidro-2H-cromen-4-il]-N'-(7-hidroxi-5,6,7,8-tetrahidronaftalen-1-il)urea; 1-(1H-indazol-4-il)-3-(espiro[croman-2,1'-ciclohexan]-4-il)urea; 1-(7-fluoroespiro[croman-2,1'-ciclohexan]-4-il)-3-(1H-indazol-4-il)urea; 1-(7-fluoroespiro[croman-2,1'-cicIobutan]-4-il)-3-(1H-indazol-4-il)urea; 1-(7-fluoroespiro[croman-2,1'-ciclobutan]-4-il)-3-(1-metil-1H-indazol-4-il)urea; 1-(6,7-dimetilespiro[croman-2,1'-ciclohexan]-4-il)-3-(1H-indazol-4-il)urea; 1-(6,8-dicloroespiro[croman-2,1'-ciclohexan]-4-il)-3-(1H-indazol-4-il)urea; 1-(6-cloroespiro[croman-2,1l-ciclohexan]-4-il)-3-(1H-indazol-4-il)urea; 1-(7-tertbutilespiro[croman-2,1'-ciclobutan]-4-il)-3-(1H-indazol-4-il)urea, 1-(6,8-difluoroespiro[croman-2,1'-ciclohexan]-4-il)-3-(1H-indazol-4-il)urea; 1-(6-etoxiespiro[croman-2,1'-ciclohexan]-4-il)-3-(1H-indazol-4-il)urea; 1-(1H-indazol-4-il)-3-(6-metilespiro[croman-2,1'-ciclopentan]-4-il)urea; 1-(7-etoxiespiro[croman-2,1'-ciclopentan]-4-il)-3-(1H-indazol-4-il)urea; 1-(6,7-dimetilespiro[croman-2,1'-ciclopentan]-4-il)-3-(1H-indazol-4-il)urea; 1-(7-fluoroespiro[croman-2,1l-ciclopentan]-4-il)-3-(1H-indazol-4-il)urea; 1-(1-metil-1H-indazol-4-il)-3-(espiro[croman-2,1'-ciclohexan]-4-il)urea; 1-(1H-indazol-4-il)-3-(7-metoxiespiro[croman-2,1'-ciclohexan]-4-il)urea; (+- )1-(3,4-dihidro-2,2-dimetil-2H-1-benzopiran-4-il)-3-(isoquinolin-5-il)urea; (+- )1-(7-cloro-3,4-dihidro-2,2-dimetil-2H-1-benzopiran-4-il)-3-(isoquinolin-5-il)urea; (+- )1-(6-bromo-3,4-dihidro-2,2-dimetil-2H-1-benzopiran-4-il)-3-(isoquinolin-5-il)urea; (+- )1-(6-metoxi-3,4-dihidro-2,2-dimetil-2H-1-benzopiran-4-il)-3-(isoquinolin-5-il)urea; (+- )1-(7-metoxi-3,4-dihidro-2,2-dimetil-2H-1-benzopiran-4-il)-3-(isoquinolin-5-il)urea; (+- )1-(6-metil-3,4-dihidro-2,2-dimetil-2H-1-benzopiran-4-il)-3-(isoquinolin-5-il)urea; (+- )1-(7-metoxi-3,4-dihidro-2,2-dimetil-2H-1-benzopiran-4-il)-3-(1-metilisoquinoIin-5-il)urea; (+- )1-(6-bromo-3,4-dihidro-2,2-dimetil-2H-1-benzopiran-4-il)-3-(1-metilisoquinolin-5-il)urea; (+- )1-(6-metil-3,4-dihidro-2,2-dimetil-2H-1-benzopiran-4-il)-3-(1-metilisoquinolin-5-il)urea; (+- )1-(3,4-dihidro-2,2-dimetil-2H-1-benzopiran-4-il)-3-(1-metilisoquinolin-5-il)urea; (+- )1-(3,4-dihidro-espiro-[2H-1-benzopiran-2,1'-ciclobutan]-4-il)-3-(isoquinolin-5-il)urea; (+)1-(3,4-dihidro-espiro-[2H-1-benzopiran-2,1'-ciclobutan]-4-il)-3-(isoquinolin-5-il)urea; (-)1-(3,4-dihidro-espiro-[2H-1-benzopiran-2,1'-ciclobutan]-4-il)-3-(isoquinolin-5-il)urea; (+- )1-(3,4-dihidro-espiro-[2H-1-benzopiran-2,1'-ciclobutan]-4-il)-3-(8-cloroisoquinolin-5-il)urea; (+- )1-(3,4-dihidro-espiro-[2H-1-benzopiran-2,1'-ciclobutan]-4-il)-3-(3-metilisoquinolin-5-il)urea; (+- )1-(3,4-dihidro-espiro-[2H-1-benzopiran-2,1'-ciclobutan]-4-il)-3-(1-metilisoquinolin-5-il)urea; (+- )1-(3,4-dihidro-6-metil-espiro-[2H-1-benzopiran-2,1'-ciclobutan]-4-il)-3-(isoquinolin-5-il)urea; (+- )1-(3,4-dihidro-7-metil-espiro-[2H-1-benzopiran-2,1'-ciclobutan]-4-il)-3-(isoquinolin-5-il)urea; (+- )1-(3,4-dihidro-6-fluoro-espiro-[2H-1-benzopiran-2,1'-ciclobutan]-4-il)-3-(isoquinolin-5-il)urea; (+)1-(3,4-dihidro-6-fluoro-espiro-[2H-1-benzopiran-2,1'-ciclobutan]-4-il)-3-(isoquinolin-5-il)urea; (-)1-(3,4-dihidro-6-fluoro-espiro-[2H-1-benzopiran-2,1'-ciclobutan]-4-il)-3-(isoquinolin-5-il)urea; (+- )1-(3,4-dihidro-7-metoxi-espiro-[2H-1-benzopiran-2,1'-ciclobutan]-4-il)-3-(isoquinolin-5-il)urea; 1-(6,8-difluoro-3,4-dihidro-espiro-[2H-1-benzopiran-2,1'-ciclobutan]-4-il)-3-(isoquinolin-5-il)urea; (+- )1-(8-cloro-3,4-dihidro-espiro-[2H-1-benzopiran-2,1'-ciclobutan]-4-il)-3-(isoquinolin-5-il)urea; (+- )1-(3,4-dihidro-6-metoxi-espiro-[2H-1-benzopiran-2,1'-ciclobutan]-4-il)-3-(isoquinolin-5-il)urea; clorhidrato de (+- )1-(7-difluorometoxi-3,4-dihidro-espiro-[2H-1-benzopiran-2,1'-ciclobutan]-4-il)-3-(isoquinolin-5-il)urea; (+- )1-(7-difluorometoxi-3,4-dihidro-espiro-[2H-1-benzopiran-2,1'-ciclobutan]-4-il)-3-(3-metilisoquinolin-5-il)urea; (+- )1-(7-cloro-3,4-dihidro-espiro-[2H-1-benzopiran-2,1'-ciclobutan]-4-il)-3-(3-metilisoquinolin-5-il)urea; (+)1-(6,8-difluoro-3,4-dihidro-espiro-[2H-1-benzopiran-2,1'-ciclobutan]-4-il)-3-(isoquinolin-5-il)urea; (-)1-(6,8-difluoro-3,4-dihidro-espiro-[2H-1-benzopiran-2,1'-ciclobutan]-4-il)-3-(isoquinolin-5-il)urea; (+- )1-(3,4-dihidro-8-difluorometoxi-espiro-[2H-1-benzopiran-2,1'-ciclobutan]-4-il)-3-(isoquinolin-5-il)urea; (+- )1-(6-cloro-3,4-dihidro-espiro-[2H-1-benzopiran-2,1'-ciclobutan]-4-il)-3-(isoquinolin-5-il)urea; (-)1-(6-cloro-3,4-dihidro-espiro-[2H-1-benzopiran-2,1'-ciclobutan]-4-il)-3-(isoquinolin-5-il)urea; (+- )1-(6-bromo-3,4-dihidro-espiro-[2H-1-benzopiran-2,1'-ciclobutan]-4-il)-3-(isoquinolin-5-il)urea; (+- )1-(6,8-dicloro-3,4-dihidro-espiro-[2H-1-benzopiran-2,1'-ciclobutan]-4-il)-3-(isoquinolin-5-il)urea; (+- )1-(6-bromo-3,4-dihidro-7-metilespiro-[2H-1-benzopiran-2,1'-ciclobutan]-4-il)-3-(isoquinolin-5-il)urea; (+- )1-(6,7-dicloro-3,4-dihidro-espiro-[2H-1-benzopiran-2,1'-ciclobutan]-4-il)-3-(isoquinolin-5-il)urea; (+- )1-(6-cloro-3,4-dihidro-7-metilespiro-[2H-1-benzopiran-2,1'-ciclobutan]-4-il)-3-(isoquinolin-5-il)urea; (+- )1-(6-cloro-3,4-dihidro-espiro-[2H-1-benzopiran-2,1'-ciclobutan]-4-il)-3-(8-cloroisoquinolin-5-il)urea; (+- )1-(6-fluoro-3
ARP090103975A 2008-10-17 2009-10-15 Antagonistas del receptor transitorio potencial de vanilloides 1 ( trpv1) utiles para tratar inflamacion y dolor AR073631A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US10636908P 2008-10-17 2008-10-17
US22007509P 2009-06-24 2009-06-24

Publications (1)

Publication Number Publication Date
AR073631A1 true AR073631A1 (es) 2010-11-17

Family

ID=41571121

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP090103975A AR073631A1 (es) 2008-10-17 2009-10-15 Antagonistas del receptor transitorio potencial de vanilloides 1 ( trpv1) utiles para tratar inflamacion y dolor

Country Status (11)

Country Link
US (1) US8604053B2 (es)
EP (1) EP2352726A1 (es)
JP (1) JP2012505907A (es)
CN (1) CN102186836A (es)
AR (1) AR073631A1 (es)
CA (1) CA2737768A1 (es)
MX (1) MX2011004081A (es)
PA (1) PA8845601A1 (es)
TW (1) TW201020236A (es)
UY (1) UY32180A (es)
WO (1) WO2010045401A1 (es)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102245587A (zh) * 2008-10-17 2011-11-16 雅培制药有限公司 Trpv1拮抗剂
US20100210682A1 (en) * 2009-02-19 2010-08-19 Abbott Laboratories Repeated Dosing of TRPV1 Antagonists
JP5934778B2 (ja) * 2011-03-25 2016-06-15 アッヴィ・インコーポレイテッド Ｔｒｐｖ１拮抗薬
WO2013096223A1 (en) 2011-12-19 2013-06-27 Abbvie Inc. Trpv1 antagonists
WO2013096226A1 (en) 2011-12-19 2013-06-27 Abbvie Inc. Trpv1 antagonists
EP2828253A1 (en) * 2012-03-19 2015-01-28 Abide Therapeutics, Inc. Carbamate compounds and of making and using same
JP6115303B2 (ja) * 2012-05-18 2017-04-19 Jnc株式会社 隣接基としてカルボニル基を有するフェノール化合物およびその用途
US8796328B2 (en) 2012-06-20 2014-08-05 Abbvie Inc. TRPV1 antagonists
WO2015179563A2 (en) 2014-05-22 2015-11-26 Abide Therapeutics, Inc. N-hydroxy bicyclic hydantoin carbamates as tools for identification of serine hydrolase targets
WO2017059135A1 (en) 2015-10-02 2017-04-06 Abide Therapeutics, Inc. Lp-pla2 inhibitors
EP3648754A4 (en) * 2017-07-06 2021-05-05 Dignity Health NEW TREATMENT FOR HEAT FLUSHING
CN108929270B (zh) * 2018-08-15 2021-06-08 上海罕道医药科技有限公司 一种药物中间体双取代含氮杂环的胺类化合物的合成
WO2020160295A1 (en) 2019-01-30 2020-08-06 Montelino Therapeutics, Llc Bi-functional compounds and methods for targeted ubiquitination of androgen receptor
JP6830569B1 (ja) 2019-08-23 2021-02-17 持田製薬株式会社 ヘテロシクリデンアセトアミド誘導体の製造方法
WO2021039023A1 (ja) 2019-08-23 2021-03-04 持田製薬株式会社 ヘテロシクリデンアセトアミド誘導体の製造方法
RU2755206C1 (ru) 2020-05-20 2021-09-14 Федеральное государственное бюджетное учреждение науки Тихоокеанский институт биоорганической химии им. Г.Б. Елякова Дальневосточного отделения Российской академии наук (ТИБОХ ДВО РАН) Средство пролонгированного анальгетического действия и лекарственный препарат на его основе
WO2024102810A1 (en) 2022-11-08 2024-05-16 Montelino Therapeutics, Inc. Bi-functional compounds and methods for targeted ubiquitination of androgen receptor

Family Cites Families (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MY115155A (en) 1993-09-09 2003-04-30 Upjohn Co Substituted oxazine and thiazine oxazolidinone antimicrobials.
JPH11512429A (ja) 1995-09-15 1999-10-26 ファルマシア・アンド・アップジョン・カンパニー アミノアリールオキサゾリジノン ｎ−オキシド
US20030220234A1 (en) * 1998-11-02 2003-11-27 Selvaraj Naicker Deuterated cyclosporine analogs and their use as immunodulating agents
GB9918037D0 (en) * 1999-07-30 1999-09-29 Biochemie Gmbh Organic compounds
GB0206876D0 (en) * 2002-03-22 2002-05-01 Merck Sharp & Dohme Therapeutic agents
GB0226724D0 (en) 2002-11-15 2002-12-24 Merck Sharp & Dohme Therapeutic agents
EP2017265B1 (en) * 2003-06-12 2011-05-25 Abbott Laboratories Fused compounds that inhibit vanilloid receptor subtype 1 (VR1) receptor
US7015233B2 (en) * 2003-06-12 2006-03-21 Abbott Laboratories Fused compounds that inhibit vanilloid subtype 1 (VR1) receptor
US7651514B2 (en) * 2003-12-11 2010-01-26 Boston Scientific Scimed, Inc. Nose rider improvement for filter exchange and methods of use
WO2005099353A2 (en) 2004-04-19 2005-10-27 Symed Labs Limited A novel process for the preparation of linezolid and related compounds
DE602004020812D1 (de) 2004-07-20 2009-06-04 Symed Labs Ltd Neue zwischenprodukte für linezolid und verwandte verbindungen
JP2008514702A (ja) * 2004-09-29 2008-05-08 エーエムアール テクノロジー インコーポレイテッド 新規シクロスポリン類似体およびそれらの薬学的使用
KR20120137420A (ko) * 2004-11-24 2012-12-20 아보트 러보러터리즈 바닐로이드 수용체 아형 1(ｖｒ1) 수용체를 억제하는 크로마닐우레아 화합물 및 이의 용도
TW200716636A (en) * 2005-05-31 2007-05-01 Speedel Experimenta Ag Heterocyclic spiro-compounds
US7514068B2 (en) * 2005-09-14 2009-04-07 Concert Pharmaceuticals Inc. Biphenyl-pyrazolecarboxamide compounds
AP2008004432A0 (en) * 2005-10-07 2008-04-30 Glenmark Pharmaceuticals Sa Substituted benzofused derivatives and their use as vanilloid receptor ligands
KR20080067361A (ko) * 2005-10-28 2008-07-18 아보트 러보러터리즈 Ｔｒｐｖ1 수용체를 억제하는 인다졸 유도체
RU2450006C2 (ru) 2006-04-18 2012-05-10 Эбботт Лэборетриз Антагонисты ванилоидного рецептора подтипа 1(vr1) и их применение
EP2083807A2 (en) 2006-10-04 2009-08-05 Neurokey A/S Use of a combination of hypothermia inducing drugs
KR20090064435A (ko) 2006-10-04 2009-06-18 뉴로키 에이/에스 허혈의 치료를 위한 저체온 유도제의 사용
US8796267B2 (en) * 2006-10-23 2014-08-05 Concert Pharmaceuticals, Inc. Oxazolidinone derivatives and methods of use
WO2008059339A2 (en) 2006-11-13 2008-05-22 Glenmark Pharmaceuticals S.A. Isoquinoline derivatives as vanilloid receptor modulators
EP2450346A1 (en) * 2006-12-20 2012-05-09 Abbott Laboratories Antagonists of the TRPV1 receptor and uses thereof
KR101222412B1 (ko) * 2007-02-15 2013-01-15 에프. 호프만-라 로슈 아게 Ｔａａｒ1 리간드로서의 2-아미노옥사졸린
WO2008110863A1 (en) 2007-03-15 2008-09-18 Glenmark Pharmaceuticals S.A. Indazole derivatives and their use as vanilloid receptor ligands
KR20100105802A (ko) * 2007-04-19 2010-09-29 콘서트 파마슈티컬즈, 인크. 중수소화된 모르폴리닐 화합물
US7531685B2 (en) * 2007-06-01 2009-05-12 Protia, Llc Deuterium-enriched oxybutynin
WO2009035598A1 (en) 2007-09-10 2009-03-19 Concert Pharmaceuticals, Inc. Deuterated pirfenidone
US20090118238A1 (en) * 2007-09-17 2009-05-07 Protia, Llc Deuterium-enriched alendronate
US20090082471A1 (en) * 2007-09-26 2009-03-26 Protia, Llc Deuterium-enriched fingolimod
US20090088416A1 (en) * 2007-09-26 2009-04-02 Protia, Llc Deuterium-enriched lapaquistat
US20090137457A1 (en) * 2007-10-02 2009-05-28 Concert Pharmaceuticals, Inc. Pyrimidinedione derivatives
US8410124B2 (en) * 2007-10-18 2013-04-02 Concert Pharmaceuticals Inc. Deuterated etravirine
US20090105338A1 (en) * 2007-10-18 2009-04-23 Protia, Llc Deuterium-enriched gabexate mesylate
KR20100090689A (ko) * 2007-10-19 2010-08-16 애보트 게엠베하 운트 콤파니 카게 Ｎ―아릴 우레아계 화합물을 함유하는 고체 분산액 생성물
AU2008317375B2 (en) * 2007-10-26 2013-02-28 Concert Pharmaceuticals, Inc. Deuterated darunavir
TW200927192A (en) * 2007-11-19 2009-07-01 Alcon Res Ltd Use of TRPV1 receptor antagonists for treating dry eye and ocular pain
CN102245587A (zh) * 2008-10-17 2011-11-16 雅培制药有限公司 Trpv1拮抗剂

Also Published As

Publication number Publication date
WO2010045401A1 (en) 2010-04-22
MX2011004081A (es) 2011-05-31
CA2737768A1 (en) 2010-04-22
US8604053B2 (en) 2013-12-10
CN102186836A (zh) 2011-09-14
PA8845601A1 (es) 2010-05-26
UY32180A (es) 2010-05-31
EP2352726A1 (en) 2011-08-10
TW201020236A (en) 2010-06-01
US20100137360A1 (en) 2010-06-03
JP2012505907A (ja) 2012-03-08

Similar Documents

Publication Publication Date Title
AR073631A1 (es) Antagonistas del receptor transitorio potencial de vanilloides 1 ( trpv1) utiles para tratar inflamacion y dolor
AR045386A1 (es) [1,8] naftiridin-2-onas y compuestos relacionados para el tratamiento de la esquizofrenia
AR061847A1 (es) Derivados de pirimidina 2- amino -5- sustituida. como inhibidores de quinasas. composiciones farmaceuticas.
CO6140033A2 (es) Amino-imidazoles y su uso como medicamento para tratar discapacidad coognotiva enfermedad de alzheimer neurodegeneracion y demencia
AR056195A1 (es) Procedimientos para preparar derivados de (etinil-bencil)-benceno sustituidos de glucopiranosilo y compuestos intermedios de los mismos
AR043111A1 (es) Derivados monoacilados de o-fenilendiaminas
AR072839A1 (es) Derivados adamantil diamida y usos de los mismos
AR084457A1 (es) Derivados de biciclo[3,2,1]octilamida
AR076550A1 (es) Inhibidores de la janus tirosina kinasa (jak)
ECSP066773A (es) Intermediarios de quinolina como inhibidores de receptores de tirosina quinasas y la síntesis de los mismos
AR043434A1 (es) Derivados de piperizacina acilados como agonistas del receptor de melanocortina-4. composiciones farmaceuticas y usos
AR054280A1 (es) Derivados de carboxamidas y su empleo en procedimientos de lucha contra enfermedades de plantas y contra hongos nocivos
AR058403A1 (es) PIRIMIDINILOXI Y PIRIDINILOXI UREAS SUSTITUíDAS COMO INHIBIDORES DE PROTEíNA QUINASAS, COMPOSICIONES FARMACÉUTICAS QUE LAS CONTIENEN Y SU USO EN LA PREPARACIoN DE UN MEDICAMENTO PARA EL TRATAMIENTO DE ENFERMEDADES MEDIADAS POR LA ACTIVIDAD BASAL DE B-RAF.
AR063454A1 (es) Derivados acetamida de diazepan como inhibidores selectivos de 11 beta - hsd1. procesos de obtencion y composiciones farmaceuticas.
AR047538A1 (es) Piridazinonas como antagonistas de las integrinas alfa4
AR049276A1 (es) Compuestos carboxamidos opiodes y composiciones farmaceuticas que los contienen
AR078786A1 (es) Derivados de la cromenona
AR060050A1 (es) Compuestos moduladores del receptor de s1p y uso de los mismos
PE20050482A1 (es) Derivados de dihidrobenzofuranilo alcanamida
AR044078A1 (es) Dihidroquinazolinas sustituidas
PE20020735A1 (es) Derivados de quinazolona como antagonistas de receptores adrenergicos alfa-1a/b
AR056861A1 (es) Compuestos triciclicos fusionados como inhibidores de la necrosis tumoral. composiciones farmaceuticas y procesos de obtencion
AR058800A1 (es) Heterociclos condensados con anillos bencenicos como inhibidores de comt, composiciones farmaceuticas que los contienen y su uso en la fabricacion de un medicamento para el tratamiento del mal de parkinson
AR057741A1 (es) Proceso para la preparacion de derivados de fenilpropargileter
AR071222A1 (es) Compuestos heterociclicos espirocondensados

Legal Events

Date Code Title Description
FA Abandonment or withdrawal